Sep 13, 2021 / 06:45PM GMT
David Neil Lebowitz - Morgan Stanley, Research Division - VP
Hello, and welcome once again to the 19th Annual Morgan Stanley Healthcare conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we get started, I'm going to go through the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I'm happy to welcome from Ironwood Pharmaceuticals, CEO, Tom McCourt, COO; Jason Rickard; and CMO, Mike Shetzline. This is a commercial stage company. You've had LINZESS, clearly a successful drug for the treatment of constipation, including IBS-C and chronic idiopathic constipation. Certainly, the company has been going through transition in recent years from the spin-off of Cyclerion. And more recently, with this effort to try and bring new assets into the fold. Could you tell us about the
Ironwood Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers